Repligen Corp. Files 8-K on Financials
Ticker: RGEN · Form: 8-K · Filed: Oct 28, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, results-of-operations
TL;DR
Repligen filed an 8-K on Oct 28, 2025, detailing financial results. Check it out.
AI Summary
Repligen Corp. filed an 8-K on October 28, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending October 28, 2025. The company is incorporated in Delaware and headquartered in Waltham, Massachusetts.
Why It Matters
This 8-K filing provides an update on Repligen Corp.'s financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Numbers
- 000-14656 — SEC File Number (Identifies the company's filing history with the SEC.)
- 04-2729386 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- REPLIGEN CORP (company) — Registrant
- October 28, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
- (781) 250-0111 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it reports on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on October 28, 2025.
What is Repligen Corp.'s principal executive office address?
The principal executive offices are located at 41 Seyon Street, Waltham, Massachusetts, 02453.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What industry is Repligen Corp. classified under?
Repligen Corp. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2025-10-28 07:33:02
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share RGEN Nasdaq Global Select
Filing Documents
- rgen-20251028.htm (8-K) — 49KB
- rgen-ex99_1.htm (EX-99.1) — 961KB
- img109360391_0.jpg (GRAPHIC) — 5KB
- 0001193125-25-252385.txt ( ) — 1162KB
- rgen-20251028.xsd (EX-101.SCH) — 27KB
- rgen-20251028_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 28, 2025, Repligen Corporation announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release by Repligen Corporation, dated October 28, 2025 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Date: October 28, 2025 By: /s/ Olivier Loeillot Olivier Loeillot President and Chief Executive Officer